Tag
A phase 1 trial reports tolerable single‑fraction preoperative stereotactic partial‑breast irradiation (30–38 Gy) with low toxicity, preserved cosmesis, and high pathologic complete response rates when surgery was delayed beyond ~9 months o
A Swedish nationwide cohort (n≈2.1M) found small but measurable variation in breast cancer risk by hormonal contraceptive formulation—higher with desogestrel/etonogestrel products and lower with levonorgestrel-containing devices; absolute e
The SUPREMO randomized trial found that postmastectomy chest‑wall irradiation reduces chest‑wall recurrence but does not improve 10‑year overall survival for intermediate‑risk breast cancer; a large real‑world analysis supports no overall s
The TUXEDO-3 trial demonstrates that patritumab deruxtecan, a HER3-targeted antibody-drug conjugate, offers clinical benefit and a manageable safety profile in metastatic breast cancer patients with active brain metastases.
Roche announces positive phase 3 results of giredestrant plus everolimus, significantly reducing disease progression risk in ER+ HER2- advanced breast cancer patients post CDK4/6 inhibitor exposure, with favorable safety and promising survi
A novel risk prediction model for 10-year heart failure or cardiomyopathy offers tailored cardiac management strategies for women undergoing breast cancer therapy.
This article reviews a joint analysis of the Joven & Fuerte and PREFER studies, highlighting disparities in fertility preservation strategies among Mexican and Italian young women with breast cancer, and discusses implications for clini
This study highlights the prognostic significance of tumor Ki-67 changes during neoadjuvant treatment, offering potential for improved risk stratification and personalized therapy in breast cancer patients.
This study offers insights into the prevalence, characteristics, and long-term survival of breast cancer patients eligible for adjuvant CDK4/6 inhibitors, highlighting real-world outcomes compared to clinical trial populations.
This retrospective UK study reveals that integrating whole-genome sequencing with clinical and mortality data enhances prognostication and identifies therapeutic targets in breast cancer, particularly in ER-positive, HER2-negative subtypes.
This study evaluates cumulative breast cancer risks among US women based on pathogenic variant status and family history, revealing significant risk stratification that informs personalized screening and prevention.
Early-onset breast cancer incidence in France has steadily increased over the past three decades, mirroring trends in other Western countries. Shifts in hormonal and lifestyle factors may contribute, highlighting the need for adapted preven
This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection
Intratumoral microbiota significantly influence breast cancer development, progression, and therapeutic response. Their diverse composition across subtypes presents diagnostic and prognostic opportunities. Emerging strategies target these m
Low-molecular-weight dextran sulfate sodium (LMW-DSS), a new heparanase inhibitor, effectively prevents breast cancer metastasis in mice by inhibiting cancer cell migration and angiogenesis, offering a promising therapeutic approach with mi
Breast cancer screening among older US women shows stable use but rising costs driven by low-value technologies; optimizing screening strategies could enhance value and reduce expenditure.
Lower-dose ribociclib (400 mg) does not demonstrate noninferior response rates compared to the standard 600 mg dose in advanced HR+/ERBB2- breast cancer but shows reduced toxicity and comparable progression-free survival, supporting 600 mg
This review synthesizes the Menopause Priority Setting Partnership findings, highlighting the top ten evidence-based research priorities addressing non-hormonal treatments, lifestyle interventions, cognitive and sleep changes, hormone thera
The PRADA II trial evaluated sacubitril-valsartan for preventing cardiac dysfunction during anthracycline-based breast cancer therapy. While it did not significantly preserve left ventricular ejection fraction, improvements in myocardial st
A phase 2 randomized trial demonstrates that targeting dormant disseminated tumor cells with hydroxychloroquine and everolimus is safe, feasible, and reduces minimal residual disease, potentially improving recurrence-free survival in breast
